Excell Research, based in Oceanside, is currently seeking participants for a new clinical trial.
In this project, called the ASPECT Study, researchers want to find out if an investigational drug called AVP-786 is safe and effective in managing agitation in adults with Alzheimer’s, when compared to a placebo. Study participants will be randomly assigned to receive either AVP-786 or placebo. The study drug will be provided as capsules to be taken by mouth, twice a day.
To be eligible for this study, a potential participant must:
- Be between the ages of 50 and 90
- Have a diagnosis of probable Alzheimer’s disease
- Have moderate-to-severe agitation that interferes with daily life
- Have a care partner who spends a minimum of 2 hours per day, 4 days per week with them and is willing and able to comply with all study procedures
This is not a complete list of study requirements. The study doctor will review all requirements with potential participants and their caregivers. The study drug and any study-related procedures and exams will be provided at no cost to participants.
If you are living with Alzheimer’s or caring for someone who is, and you would like to learn more about this research opportunity, please visit www.excellresearch.com or call Excell Research at 760-758-2222.
